SCHEMBL25824549

SCHEMBL25824549

COc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1N1CCC(=O)NC1=O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 5/20 0.48
▸ CRBN Q96SW2 5/20 0.48
▸ LMNA P02545 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ PDK2 Q15119 1/20 0.45
▸ ALK Q9UM73 5/20 0.45
▸ ABCB1 P08183 2/20 0.44
▸ NR3C1 P04150 1/20 0.43
▸ PGR P06401 1/20 0.43
▸ SLC6A4 P31645 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ PDE3B Q13370 1/20 0.43
▸ PDE3A Q14432 1/20 0.43
▸ SUV39H2 Q9H5I1 3/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ P2RX7 Q99572 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25034753 0.92 DDB1 (0.48) DDB1CRBNLMNAMAPTALDH1A1
SCHEMBL31630916 0.92 DDB1 (0.48) DDB1CRBNLMNAMAPTALDH1A1
SCHEMBL30952388 0.88 DDB1 (0.50) DDB1CRBNLMNAMAPTALDH1A1
SCHEMBL30643667 0.87 DDB1 (0.49) DDB1CRBNLMNAMAPTALDH1A1
SCHEMBL29264332 0.86 DDB1 (0.51) DDB1CRBNLMNAMAPTALDH1A1
SCHEMBL25941790 0.86 CRBN (0.47) DDB1CRBNLMNAALDH1A1PDK2
SCHEMBL31630927 0.85 DDB1 (0.49) DDB1CRBNLMNAMAPTALDH1A1
SCHEMBL22119507 0.84 DDB1 (0.59) DDB1CRBNLMNAMAPTALDH1A1
SCHEMBL29265203 0.82 CRBN (0.55) DDB1CRBNLMNAMAPTALDH1A1
SCHEMBL30525413 0.82 CRBN (0.55) DDB1CRBNLMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118271284-A Estrogen receptor modulators and uses thereof 江苏威凯尔医药科技有限公司 2024-07-02 — — CN disclosed
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 — — US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 — — US disclosed
CN-116322700-A Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2023-06-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 DDB1 132/4885CRBN 2136/4885LMNA 2201/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 DDB1 77/4885CRBN 2496/4885LMNA 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback